Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05411744 · ClinicalTrials.gov registry record · Phase 4
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
A Phase 4 study of End Stage Renal Disease and Latent Tuberculosis, sponsored by Rutgers, The State University of New Jersey.
- Active
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05411744: Active Phase 4 study of End Stage Renal Disease and Latent Tuberculosis, sponsored by Rutgers, The State University of New Jersey.
NCT05411744 is a Phase 4 study of End Stage Renal Disease and Latent Tuberculosis that is active but no longer recruiting, run by Rutgers, The State University of New Jersey. The registered enrollment target is 25 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05411744, a Phase 4 study of End Stage Renal Disease and Latent Tuberculosis, is active but no longer recruiting, sponsored by Rutgers, The State University of New Jersey.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
Primary Outcome
Treatment discontinuation due to adverse reaction of study drug determined by investigator
Conditions Studied
Interventions
- DRUG 1 month Rifapentine, Isoniazid and Vitamin B6
Study Locations (1)
New Jersey
- Pinki J Bhatt - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 4 |
What the registry record for NCT05411744 still lists
NCT05411744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which 1 month Rifapentine, Isoniazid and Vitamin B6 is the first listed.
NCT05411744 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05411744 about?
NCT05411744 is a clinical study titled "One-month Latent Tuberculosis Treatment for Renal Transplant Candidates". This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
What is the current status of trial NCT05411744?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2022-07-01. Estimated completion is 2029-06-30.
What conditions does trial NCT05411744 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Latent Tuberculosis, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney.
What interventions are being tested in trial NCT05411744?
The interventions under investigation include: 1 month Rifapentine, Isoniazid and Vitamin B6 (DRUG).
Who is sponsoring clinical trial NCT05411744?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05411744 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05411744's enrollment target sits among peer trials
25 66th of 86 higher than 21 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ferric Citrate in ESRD Pilot Project
ACTIVE NOT RECRUITING · Phase 4
-
Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients
COMPLETED · Phase 4
-
A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP
COMPLETED · Phase 4
-
Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
COMPLETED · Phase 4
-
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
COMPLETED · Phase 4
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI